Combination of TAFIa inhibitor with plasminogen activator
AssigneeDaiichi Sankyo Company, Limited
InventorsKengo Noguchi, Yusuke Ito, Naoko Edo
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.
Claims35
A pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a compound of formula (I):
- or a pharmacologically acceptable salt thereof, and
- a plasminogen activator,
- wherein R is a hydrogen atom, a [(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl group, a [1-(isobutyryloxy)ethoxy]carbonyl group, a [1-(2,2-dimethylpropanoyloxy)ethoxy]carbonyl group, a {1-[(cyclohexylcarbonyl)oxy]ethoxy}carbonyl group, or a (1-acetoxyethoxy)carbonyl group, and
- the pharmaceutical composition exhibits synergistic fibrinolytic activity.
A method of treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a compound of formula (I):
- or a pharmacologically acceptable salt thereof, in combination with a plasminogen activator to a warm-blooded animal,
- wherein R is a hydrogen atom, a [(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl group, a [1-(isobutyryloxy)ethoxy]carbonyl group, a [1-(2,2-dimethylpropanoyloxy)ethoxy]carbonyl group, a {1-[(cyclohexylcarbonyl)oxy]ethoxy}carbonyl group, or a (1-acetoxyethoxy)carbonyl group, and
- the method exhibits synergistic fibrinolytic activity.
Dependencies are inferred from the claim text.